Plessey announced today that they will be exhibiting at the International IC China Exhibition in Shenzhen from 28 February to 2 March 2013. Plessey will be featuring solutions for the tele-health markets including the handheld imPulse™ and the wrist worn inCite™ incorporating the company's award winning EPIC™ sensor.
Research and Markets has announced the addition of the "Biosensors in Medical Diagnostics - Global Strategic Business Report" report to their offering.
Freescale Semiconductor has designed a fully integrated microcontroller (MCU) solution that powers the second generation of Insulet’s OmniPod, the revolutionary tubeless, wireless insulin pump. Freescale’s integrated technology has helped make the new OmniPod one-third smaller, one-quarter lighter and much more power-efficient to help people with diabetes lead a more active life.
Researchers have given rats the ability to "touch" infrared light, normally invisible to them, by fitting them with an infrared detector wired to microscopic electrodes implanted in the part of the mammalian brain that processes tactile information. The achievement represents the first time a brain-machine interface has augmented a sense in adult animals, said Duke University neurobiologist Miguel Nicolelis, who led the research team.
Tensys Medical, Inc., a leader in the development and commercialization of continuous, non-invasive hemodynamic patient monitoring systems, has entered into a commercial agreement with Zhejiang Shanshi Medical Device CO., LTD (Shanshi) for distribution of the company’s T-Line technology.
Researchers from the Universitat Autònoma de Barcelona (UAB), led by Fàtima Bosch, have shown for the first time that it is possible to cure diabetes in large animals with a single session of gene therapy. As published this week in Diabetes, the principal journal for research on the disease, after a single gene therapy session, the dogs recover their health and no longer show symptoms of the disease. In some cases, monitoring continued for over four years, with no recurrence of symptoms.
Pepex Biomedical, Inc. announced today it will enter the mHealth arena by incorporating Machine-to-Machine (M2M) network capabilities in all of its diagnostic medical devices reflecting the company's confidence in the underlying proprietary technology. Pepex will begin with the Trio™ line of blood glucose devices and sees M2M as an ideal wireless diabetes care solution that can bridge the current generation of smartphone based health apps to become a true wireless monitoring solution for diabetes.
Awarepoint Corporation, the largest real-time location system (RTLS) corporation dedicated exclusively to healthcare, announces the launch of its new Bed and Bay Sensor that enables precise tracking of mobile equipment and patient and caregiver interactions in locations with tight-bed spacing, such as the emergency department (ED) and pre- and post-anesthesia care.
Adults living with diabetes in the United States reported highest satisfaction using Roche Diabetes Care's ACCU-CHEK products compared with other blood glucose meter manufacturers, according to the inaugural J.D. Power and Associates 2012 Blood Glucose Meter Satisfaction StudySM. Diabetes affects a large portion of the U.S. population – 25.8 million children and adults or approximately 1 in 12 people.
UT Dallas researchers are extending the borders of virtual reality, going beyond virtual spaces in which people can see and hear one another to an environment that adds the sense of touch.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.